Skin Advanced Glycation End Products among Subjects with Type 2 Diabetes Mellitus with or without Distal Sensorimotor Polyneuropathy

Table 3

ROC analysis for the evaluation of the diagnostic significance of AGEs (single measurement) for large fibre impairment, small fibre impairment, and overall DSPN.

	Large fibre	value	Small fibre	value	Overall DSPN	value
AUC (95% CI)	0.766 (0.671-0.861)	<0.001	0.765 (0.685-0.846)	<0.001	0.790 (0.712-0.869)	<0.001
Cut-off	≥3.15		≥2.75		≥2.95
Sensitivity (%)	61.8 (43.6-77.8)		74.0 (62.4-83.6)		69.0 (55.5-80.5)
Specificity (%)	79.6 (70.3-87.1)		69.5 (56.1-80.8)		77.0 (65.8-86.0)
PPV (%)	51.2 (39.6-62.7)		75.0 (66.6-81.9)		70.2 (60.0-78.7)
NPV (%)	85.7 (79.5-90.3)		68.3 (58.6-76.7)		76.0 (67.9-82.6)
Overall agreement (%)	75.0		72.0		73.5
Cohen’s kappa	0.388	<0.001	0.434	<0.001	0.461	<0.001
OR (95% CI)	6.30 (2.70-14.72)	<0.001	6.47 (3.02-13.87)	<0.001	7.45 (3.43-16.20)	<0.001

AUC: area under the curve; CI: confidence interval; DSPN: distal sensorimotor polyneuropathy; NPV: negative predictive value; OR: odds ratio; PPV: positive predictive value.